Management ChangeApr 22, 2026, 09:03 AM
BBOT Appoints Pedro Beltran as CEO, Idan Elmelech as COO
AI Summary
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced significant leadership changes, appointing Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer, effective April 20, 2026. Neil Kumar, PhD, a co-founder, was named Executive Chairman, while former CEO Eli Wallace, PhD, transitioned to Senior Adviser. These appointments are intended to guide BBOT through its next development phase as its clinical assets advance into expansions and combinations for RAS-driven cancers, aiming for accelerated program development and strategic execution.
Key Highlights
- Pedro J. Beltran, PhD, appointed Chief Executive Officer, effective April 20, 2026.
- Idan Elmelech appointed Chief Operating Officer, effective April 20, 2026.
- Neil Kumar, PhD, a co-founder, named Executive Chairman by the Board of Directors.
- Former CEO Eli Wallace, PhD, will serve as a Senior Adviser to the company.
- Leadership changes aim to accelerate development as clinical assets enter new phases.